BRISTOL MYERS SQUIBB

The FDA has granted breakthrough therapy designation to iza-bren, a first-in-class bispecific antibody-drug conjugate developed by Bristol Myers Squibb and SystImmune for treating advanced EGFR-mutant lung cancer.

Bristol-Myers Squibb, Exelixis, and Novartis are collaborating on the Pan-Tumor Rollover Study to evaluate the long-term safety of nivolumab monotherapy and its combinations across various tumor types.

X4 Pharmaceuticals announced a $60 million private placement financing led by Coastlands Capital, Bain Capital Life Sciences, and New Enterprise Associates to support continued development of mavorixafor.

IO Biotech's cancer vaccine Cylembio combined with Keytruda showed a 23% relative risk reduction in disease progression or death compared to Keytruda alone, but narrowly missed statistical significance with a p-value of 0.056.

GSK's anti-TIM-3 monoclonal antibody cobolimab failed to improve overall survival in the Phase III COSTAR trial for advanced non-small cell lung cancer patients previously treated with immunotherapy.

Bristol Myers Squibb and Bain Capital have formed an independent company backed by $300 million to develop five experimental immunology drugs licensed from Bristol Myers.

Bristol Myers Squibb has appointed Cristian Massacesi, M.D., former AstraZeneca Chief Medical Officer, as Executive Vice President, Chief Medical Officer, and Head of Development, effective August 1, 2025.

Dispatch Bio, a new biotech company formed through collaboration between Arch Venture Partners and the Parker Institute for Cancer Immunotherapy, has raised $216 million to develop a universal solid tumor treatment approach.

Ryan Richardson will step down as Chief Strategy Officer from BioNTech's Management Board on September 30, 2025, after serving since January 2020.

Bristol Myers Squibb's anemia drug Reblozyl failed to meet its primary endpoint of red blood cell transfusion independence in the Phase III INDEPENDENCE trial for myelofibrosis patients.